GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Fennec Pharmaceuticals Inc (STU:RV41) » Definitions » Short Interest

Fennec Pharmaceuticals (STU:RV41) Short Interest


View and export this data going back to . Start your Free Trial

What is Fennec Pharmaceuticals Short Interest?

Short Interest can be expressed as a percentage by dividing the number of shares sold short by the total number of outstanding shares.

Due to the license agreement change with our data vendor, Short Interest related data is no longer available on GuruFocus website.

Competitive Comparison of Fennec Pharmaceuticals's Short Interest

For the Biotechnology subindustry, Fennec Pharmaceuticals's Short Interest, along with its competitors' market caps and Short Interest data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Fennec Pharmaceuticals's Short Interest Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Fennec Pharmaceuticals's Short Interest distribution charts can be found below:

* The bar in red indicates where Fennec Pharmaceuticals's Short Interest falls into.


Fennec Pharmaceuticals (STU:RV41) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Fennec Pharmaceuticals Inc (STU:RV41) » Definitions » Short Interest
Comparable Companies
TSX:MDNA TSXV:NGEN NEOE:CYBN TSX:EPRX XCNQ:ACOG TSX:ONC TSXV:ARCH XCNQ:METX TSX:SVA TSX:TH OCSE:NOVO B VRTX REGN ASX:CSL MRNA XKRX:207940 XKRX:068270 XBRU:UCB BNTX XBRU:ARGX
Traded in Other Exchanges
FENC:USA FRX:Canada
Address
68 TW Alexander Drive, PO Box 13628, Research Triangle Park, NC, USA, 27709
Website
https://www.fennecpharma.com
Fennec Pharmaceuticals Inc is a clinical-stage biotechnology company. It is engaged in research and development activities. The company is developing Sodium Thiosulfate (STS), a chemo-protectant against hearing loss associated with platinum-based chemotherapy. Its product candidate is PEDMARK which is sodium thiosulfate in a novel formulation for the prevention of cisplatin induced hearing loss, or ototoxicity in children. The company principally operates in the United States.

Fennec Pharmaceuticals (STU:RV41) Headlines

No Headlines